Huijie Bian

19PUBLICATIONS
43CO-AUTHORS
Predictive and prognostic markersCellular immunologyPharmaceutical delivery technologiesMedical infection agents (incl. prions)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (19)

|Jun 26, 2026
Paraoxonase 1 Suppresses Hepatocellular Carcinoma Progression by Modulating the NOD-like Receptor Signaling Pathway.

|Feb 02, 2026
Inducible CD147 up-regulation boosts extended SARS-CoV-2 infection triggering severe COVID-19 independent of ACE2.

Ke Wang, Peng Lin, Ruo Chen

|Dec 27, 2025
CD147/Basigin: From Integrative Molecular Hub to Translational Therapeutic Target.

Xiang-Min Yang, Huijie Bian, Zhi-Nan Chen

|Dec 18, 2025
CD147 promotes NSCLC metastasis by inducing secretory autophagy-dependent exosome secretion via TRIM56-mediated ubiquitination and degradation of GCN2.

Jie Yang, Chenggong Liao, Xiaohua Liang

|Apr 13, 2025
Meplazumab, a CD147 antibody, for severe COVID-19: a double-blind, randomized, placebo-controlled, phase 3 clinical trial.

Huijie Bian, Liang Chen, Zheng Zhang

|Jan 03, 2024
CD147 Sparks Atherosclerosis by Driving M1 Phenotype and Impairing Efferocytosis.

Jian-Jun Lv, Hao Wang, Cong Zhang

Pageof 4

Frequent Collaborators

6 joint publications

Zhinan Chen

4 joint publications

Chuan Qin

4 joint publications

Ke Wang

3 joint publications

Ze-Kun Liu